胸部CT诊断的肌少症可预测慢性阻塞性肺疾病急性加重危重患者的长期死亡率
这项回顾性研究纳入2018至2023年148例因ECOPD入住ICU的患者,通过胸部CT第12胸椎水平的骨骼肌指数定义肌少症。84例(56.76%)存在肌少症,其1年COPD相关死亡率(19.05% vs 4.69%,p=0.010)、1年全因死亡率(28.57% vs 6.25%,p=0.001)、总体COPD相关死亡率(33.33% vs 15.63%,p=0.015)及总体全因死亡率(47.62% vs 29.69%,p=0.027)均显著高于非肌少症组。
要点
- 胸部CT第12胸椎水平测量的骨骼肌指数可诊断肌少症,ECOPD危重患者中检出率达56.76%。
- 肌少症组1年COPD相关死亡率19.05% vs 非肌少症组4.69%,1年全因死亡率28.57% vs 6.25%。
- 肌少症是1年死亡率(HR=3.981)和总体死亡率(HR=2.308)的风险因素。
核心结论
- 胸部CT第12胸椎水平评估的肌少症可能作为预测ECOPD危重患者长期死亡率的预后因素。
研究设计与样本
- 回顾性研究,纳入2018至2023年因ECOPD入住ICU的148例患者,以胸部CT第12胸椎水平的骨骼肌指数定义肌少症,分为肌少症组和非肌少症组,比较住院时长、短期(30天和90天)及长期(1年和总体)COPD相关死亡率和全因死亡率,并进行Cox回归分析和构建基于肌少症的列线图。
诊断标准与关键数值
- 肌少症定义为胸部CT第12胸椎水平的骨骼肌指数测量值。
- 1年COPD相关死亡率:肌少症组19.05% vs 非肌少症组4.69%(p=0.010)。
- 1年全因死亡率:肌少症组28.57% vs 非肌少症组6.25%(p=0.001)。
- 总体COPD相关死亡率:肌少症组33.33% vs 非肌少症组15.63%(p=0.015);总体全因死亡率:肌少症组47.62% vs 非肌少症组29.69%(p=0.027)。
临床应用与阅片要点
- 在胸部CT阅片时可利用第12胸椎水平骨骼肌指数识别肌少症,辅助ECOPD危重患者的预后评估。
- 基于肌少症的列线图显示出良好的预后预测性能,可作为预后分层参考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Sarcopenia is a prevalent comorbidity in patients with chronic obstructive pulmonary disease (COPD). We aimed to investigate the impact of sarcopenia diagnosed by chest CT on mortality in critically ill patients with exacerbation of COPD (ECOPD).
METHODS: This retrospective study enrolled 148 patients hospitalized in the intensive care unit due to ECOPD from 2018 to 2023. Sarcopenia was defined by the skeletal muscle index measured at the 12th thoracic vertebra (T12) level on chest CT. Patients were categorized into the sarcopenia and non-sarcopenia groups. Hospitalization duration, short-term (30 and 90-day) and long-term (1-year and overall) COPD-related mortality and all-cause mortality were compared between the two groups. Cox regression analyses were conducted to recognize the risk factors for mortality, and a sarcopenia-based nomogram was developed.
RESULTS: Eighty-four patients (56.76 %) with sarcopenia were identified through chest CT measurements. The 1-year COPD-related and all-cause mortality, as well as overall COPD-related and all-cause mortality, were significantly higher in the sarcopenia group than the non-sarcopenia group (19.05 % vs. 4.69 %, p = 0.010; 28.57 % vs. 6.25 %, p = 0.001; 33.33 % vs. 15.63 %, p = 0.015; 47.62 % vs. 29.69 %, p = 0.027, respectively). Multivariate Cox regression analyses revealed sarcopenia as a risk factor for 1-year (HR = 3.981 [1.137-13.938], p = 0.031) and overall (HR = 2.308 [1.310-4.065], p = 0.004) mortality. The sarcopenia-based nomogram demonstrated favorable prognostic performance.
CONCLUSIONS: Sarcopenia evaluated at the T12 level on chest CT may serve as a prognostic factor for predicting long-term mortality among critically ill patients with ECOPD.
引用
- Dai X, Zhou Q, Wang Q, et al. Sarcopenia diagnosed by chest CT predicts long-term mortality in critically ill patients with exacerbation of chronic obstructive pulmonary disease. Eur J Radiol. 2025. PMID: 40849991. doi:10.1016/j.ejrad.2025.112373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。